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Summary
Objective: Periosteum contains undifferentiated mesenchymal stem cells that have both chondrogenic and osteogenic potential, and has
been used to repair articular cartilage defects. During this process, the role of growth factors that stimulate the periosteal mesenchymal cells
toward chondrogenesis to regenerate articular cartilage and maintain its phenotype is not yet fully understood. In this study, we examined
the effects of insulin-like growth factor-1 (IGF-1) and transforming growth factor-1 (TGF-1), alone and in combination, on periosteal
chondrogenesis using an in vitro organ culture model.
Methods: Periosteal explants from the medial proximal tibia of 2-month-old rabbits were cultured in agarose under serum free conditions for
up to 6 weeks. After culture the explants were weighed, assayed for cartilage production via Safranin O staining and histomorphometry,
assessed for proliferation via proliferative cell nuclear antigen (PCNA) immunostaining, and assessed for type II collagen mRNA expression
via in situ hybridization.
Results: IGF-1 significantly increased chondrogenesis in a dose-dependent manner when administered continuously throughout the culture
period. Continuous IGF-1, in combination with TGF-1 for the first 2 days, further enhanced overall total cartilage growth. Immunohisto-
chemistry for PCNA revealed that combining IGF-1 with TGF-1 gave the strongest proliferative stimulus early during chondrogenesis. In situ
hybridization for type II collagen showed that continuous IGF-1 maintained type II collagen mRNA expression throughout the cambium layer
from 2 to 6 weeks.
Conclusion: The results of this study demonstrate that IGF-1 and TGF-β1 can act in combination to regulate proliferation and differentiation
of periosteal mesenchymal cells during chondrogenesis. © 2003 OsteoArthritis Research Society International. Published by Elsevier
Science Ltd. All rights reserved.
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Damaged articular cartilage is well known to have a limited
potential for repair or regeneration due to its avascularity
and the presence of relatively few cells with low mitotic
activity1,2. Articular cartilage damage is a major cause of
degenerative arthritis. Biological resurfacing of damaged
articular cartilage with free periosteal grafts has been
shown to be possible in experimental models3–7 and in
clinical studies8–10. Periosteum contains undifferentiated
mesenchymal stem cells in the cambium layer, which can
undergo both osteogenesis and chondrogenesis11–14. In
normal bone growth, these cells directly differentiate into
osteoblasts during intramembranous ossification without
passing through a chondrogenic lineage11,12. In fracture55healing and callus distraction, these cells differentiate into
chondrocytes as a part of endochondral ossification13,14.
However, the factors that regulate periosteal chondrogen-
esis are relatively unknown. To address this phenomenon,
we have established an agarose suspension periosteal
organ culture model15. In this system, exogenous trans-
forming growth factor-1 (TGF-1) and fetal bovine serum
(FBS) containing undefined concentrations of growth
factors and binding proteins are necessary to induce
chondrogenesis15. This suggests that growth factors play
an important role in inducing periosteal chondrogenesis
and maintaining its cartilaginous phenotype. Among these
growth factors, insulin-like growth factor-1 (IGF-1) and
TGF-1 are normally present in articular cartilage16,17
and are among the most potent regulators of proliferation
and differentiation of chondrocytes.
IGF-1 has been reported to predominantly stimulate
matrix synthesis with a minor effect on mitotic activity in
articular chondrocytes16,18–20. Kato et al., have also shown
that chondrocytes synthesize IGF-121,22. IGF-1 has been
found to maintain the steady-state metabolism of proteo-
glycans in bovine articular cartilage explants16 and to
accelerate proliferation and differentiation of cartilage
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PERIOSTEAL EXPLANTS AND TISSUE CULTURES
All work in this study was conducted with the approval
of the Mayo Clinic Institutional Animal Care and Use
Committee. One hundred and eleven small (1.5×2 mm)
and 96 large (3×4 mm) periosteal explants were harvested
by sharp subperiosteal dissection4 from the medial side
of both proximal tibiae of 30 two-month-old male New
Zealand White rabbits weighing an average of 1.8 kg.
All periosteal explants were obtained within 30 min after
death to control for post-mortem effects on the chondro-
genic potential32. The small explants were used for histo-
morphometry and the large explants were used for
immunohistochemistry and in situ hybridization.
The explants were cultured in agarose using a previously
described method15 under serum-free conditions. Immedi-
ately after surgical harvesting, the periosteal explants were
placed in Dulbecco’s Modified Eagle Medium (DMEM)
(Life Technologies, Grand Island, NY), with penicillin/
streptomycin (50 U/ml and 50 g/ml) (Life Technologies)
and 1 mM proline (Sigma Chemical Co., St. Louis, MO) at
4°C for no more than 1.5 h prior to placement into culture
wells. Twenty-four-well flat-bottom culture plates (Corning
Glass Works, Corning, NY) were precoated with high Tm
agarose gel (Bio-Rad Laboratories, Richmond, CA). The
explants were suspended in 1 ml of a 1:1 mixture of 1.0%
low Tm agarose gel (Bio-Rad Laboratories) and 2× concen-
tration of DMEM. The final suspension agarose gel con-
tained 0.5% low Tm agarose gel, 1×DMEM, 1 mM proline
and penicillin/streptomycin (50 U/ml and 50 g/ml). The
agarose gel was allowed to fully congeal at 4°C for 5 min.
Each 1.0 ml of gel layer was covered with 1.0 ml of DMEMcontaining 1 mM proline, penicillin/streptomycin (50 U/ml
and 50 g/ml), 50 g/ml ascorbic acid, and 0.1%
radioimmunoassay-grade bovine serum albumin (BSA)
(Sigma). The medium above the gel layer was replaced
every second day. Ascorbic acid was added daily for a final
concentration of 25 g/ml. Cultures were maintained at
37°C and 5% CO2/95% air for 1, 2, 3, 4, 5 or 6 weeks.
IGF-1 and/or TGF-1 were added to the medium as
follows. Recombinant human insulin-like growth factor-I
(IGF-1) (R & D Systems, Minneapolis, MN) was used in
concentrations of 5, 10, 50, 100 and 500 ng/ml (to deter-
mine the optimal dose) for 6 weeks (added every other day)
or for the first 2 days of culture. Ten ng/ml porcine trans-
forming growth factor-1 (TGF-1) (R & D Systems) was
used only for the first 2 days of culture as previously
described33–35. The treatment duration of two days was
chosen for TGF-1 because it has been observed that a
longer duration, specifically 14 days of TGF-1, does not
result in improved chondrogenesis vs two days of treat-
ment36. The growth factors were also added to the DMEM
used to make the agarose suspension gel so that the
concentration was homogeneously distributed throughout
the agarose gel and liquid culture medium.HISTOMORPHOMETRY
After 6 weeks of culture, a total of 111 small explants
were weighed using a Mettler AT261 DeltaRange® balance
accurate to 0.01 mg (Mettler-Toledo, Inc. Columbus, Ohio
43240), fixed in 10% neutral buffered formalin, and embed-
ded in paraffin. Three m thick sections were cut perpen-
dicular to the original cambium surface of the periosteum
from the middle and stained with Safranin O/Fast Green.
They were analysed by a blinded observer using compu-
terized histomorphometry to determine the percentage of
the area that was cartilage in the section37. This was
performed with a custom-designed software application
using the Vidas 2.1 Image Analysis Program from Zeiss
(Kontron customized by Carl Zeiss Canada, Don Mills,
Ontario, Canada). The analysis of cartilage is based on the
uptake of Safranin O stain, with the thresholds and combi-
nations of red, green and blue colors distinguished auto-
matically. With the cartilaginous areas staining red with
Safranin O and the non-cartilaginous areas staining blue-
green with Fast Green, the computer calculates the carti-
lage yield (i.e. percent area of cartilage) in each explant by
measuring the red-stained region of the histological section
and by expressing it as a percentage of the whole section’s
area37. The total amount of cartilage was calculated by
multiplying % cartilage by wet weight.TISSUE PREPARATION FOR IMMUNOHISTOCHEMISTRY AND IN SITU
HYBRIDIZATION
After 1, 2, 3, 4, 5 and 6 weeks of culture, a total of 96
large explants were fixed in 4% paraformaldehyde/sodium
phosphate buffer (pH 7.4) for 4 h at 4°C, and embedded in
paraffin. Serial histological sections, 4 m in thickness,
were cut same as above. Each section was stained with
Safranin O/Fast Green and analysed by histomorphometry
as described above. These Safranin O sections were also
used to evaluate the preservation of the cambium layer or
cartilage and fibrous layers. Of these original 96 large
explants, 90 were used for immunohistochemistry and
in situ hybridization because they had a well-preservedprogenitor cells in cultures of neonatal mandibular con-
dyles23. Lindhal et al., studied the effect of GH and IGF-1
on colony formation from chondrocytes obtained at different
stages of maturation in suspension culture. The growth
plate was dissected into three zones (proximal, intermedi-
ate, and distal) corresponding to the germinative, prolifer-
ative, and hypertrophic cell layers. IGF-1 (100 ng/ml)
increased the number of colonies from the proximal zone
by 182±18% and in the intermediate zone by 195±12%.
There was little or no effect in the distal zone24.
The effects of TGF-1 on articular chondrocytes are
dependent on the conditions of the target cells. TGF-1 has
been shown to stimulate or inhibit cell proliferation25,26
and proteoglycan synthesis27,28 in cultured articular
chondrocytes. In cultured periosteal explants, Miura et al.,
demonstrated that TGF-1 administration stimulates
chondrogenesis in a dose dependent manner29. It has
also been shown in cultured periosteal explants that the
exogenous administration of TGF-1 up-regulates the
endogenous expression of TGF-130,31 and its receptors31.
These lines of evidence suggest that both IGF-1 and
TGF-1 are potentially important regulators of periosteal
chondrogenesis. Therefore, it is essential to understand the
effects of these growth factors on periosteal mesenchymal
cells. Additionally, such understanding would be relevant to
fracture healing or callus distraction to which periosteum
contributes. In this study, we report the effects of IGF-1 and
TGF-1 (individually and combined) on proliferation, type II
collagen mRNA expression and cartilage formation from
periosteal mesenchymal cells during chondrogenesis in
vitro under serum-free conditions.
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excluded because of damage to the cambium layer in these
explants, which may cause decreased chondrogenic
activity33.IMMUNOHISTOCHEMISTRY
To detect and localize the cells undergoing proliferation,
immunohistochemistry for proliferative cell nuclear antigen
(PCNA) was performed. PCNA is an important auxiliary
protein for DNA polymerase 38, and has been shown to
clearly correlate with cell proliferation39–41. The sections
were deparaffinized with xylene and hydrated with serial
concentrations of 100, 95, 80 and 60% ethanol. Endogen-
ous peroxidase activity was blocked with 0.6% hydrogen
peroxide in methanol for 1 h. Following three washes in
tris-buffered saline (TBS)/0.1% BSA, non-specific binding
of antibody was blocked with 1.5% normal horse serum
(Vector Laboratories, Burlingame, CA) in TBS/0.5% BSA
for 15 min at room temperature. The sections were then
incubated with mouse monoclonal antibodies against
PCNA (Sigma) diluted at 1:1000 overnight at room tem-
perature in a humidified chamber. After three washes in
TBS/0.1% BSA, sections were incubated with biotinylated
horse antimouse IgG (Vector Laboratories) for 1 h at room
temperature. Following three washes in TBS/0.1% BSA,
avidin-biotin complex (Vector Laboratories) was applied
for 30 min at room temperature. After extensive washes,
the sections were reacted with diaminobenzidine (DAB)
(Sigma) for 2 min, then dehydrated and mounted. Mouse
IgG (Sigma) was used as a control primary antibody.IN SITU HYBRIDIZATION
Rabbit specific degoxigenin (DIG)-labeled antisense and
sense cRNA probes for type II collagen were generated
from 269 base pair cDNA fragment of rabbit type II colla-
gen42. Rabbit type II collagen cDNA was obtained by PCR
with degenerate primers based on conserved sequences
among species42,43. For the antisense probe, the corre-
sponding template had a T7 promoter sequence at the 3′
end of the template provided in the 3′ primer. Similarly for
the sense probe, the corresponding template had a T7
promoter sequence at the 5′ end of the template provided
in the 5′ primer. Degoxigenin-labeled antisense and sense
cRNA probes were transcribed using DIG-RNA Labeling Kit
(Roche Molecular Biochemicals, Mannheim, Germany) on
the cDNA templates that had T7 promoter sequences.
In situ hybridization was performed according to the
method described by Nomura et al.44. The sections were
deparaffinized with xylene, hydrated with serial concen-
trations of 100, 90, 80 and 70% ethanol followed by two
washes in sodium phosphate buffer, and were then per-
meabilized with 5 g/ml proteinase K (Roche Molecular
Biochemicals) in 10 mM Tris-HCl, 1 mM EDTA (pH 8.0) at
37°C for 7.5 min. The sections were re-fixed in 4%
paraformaldehyde/sodium phosphate buffer, rinsed with
sodium phosphate buffer, and treated with 0.2 M HCl for
10 min to inactivate endogenous alkaline phosphatase
(AP). After a wash in sodium phosphate buffer, sections
were acetylated with 0.25% acetic anhydride in 0.1 M
Triethanolamine-HCl for 10 min, and dehydrated with
ethanol. The sections were then incubated with DIG-
labeled antisense or sense probes in hybridization buffer
(Amersham, Uppsala, Sweden) at 50°C for 16 h in ahumidified chamber. After hybridization, the sections were
washed in 5×saline-sodium citrate (SSC) at 50°C, 2×SSC,
50% formamide at 50°C for 30 min, and then treated with
10 g/ml RNAse A (Sigma) at 37°C for 30 min followed by
washes in 2×SSC and two of 0.2×SSC at 50°C for 20 min
each. Non-specific binding of antibody was blocked with
1.5% blocking reagent (Roche Molecular Biochemicals) in
TBS for 1 h. The sections were incubated with anti-DIG-AP
Fab fragment (Roche Molecular Biochemicals) diluted at
1:500 for 30 min. After two washes in TBS for 15 min,
AP activity was reacted with 4-Nitro blue tetrazolium
chloride (NBT)/5-Bromo-4-chloro-3-iodolyl-phosphate (BCIP)
(Roche Molecular Biochemicals).QUANTIFICATION FOR IMMUNOHISTOCHEMISTRY AND IN SITU
HYBRIDIZATION
The number of cells expressing PCNA and type II
collagen mRNA was assessed using a published cell count-
ing technique35,45. Cambium, cartilage and fibrous area in
periosteal explants were identified in sections stained with
Safranin O/Fast Green. Only cells within the cambium and
cartilage area were included. The total number of cells and
the number of positive stained cells were counted with
three randomly selected microscopic fields (at ×200 mag-
nification) per each section. This analysis was done on 3 to
4 different explants per experimental group. The positive
ratio for each field (i.e. proliferation index for PCNA and
expression index for in situ) was calculated by dividing the
number of positive stained cells by the total number of cells.STATISTICAL ANALYSES
Statistical analyses were performed using 1 factor
ANOVA and Duncan’s New Multiple Range post-hoc
testing. All data are expressed as mean±standard error.Results
Chondrogenesis was determined by measuring the
percentage of the tissue in the explants that was cartilage,
as well as by calculating the total quantity of cartilage. The
addition of IGF-1 (50, 100 or 500 ng/ml), alone for the first
2 days did not significantly increase cartilage formation
(data not shown). However, when IGF-1 was added at
these doses continually for 6 weeks, there was a marked
increase both in the percentage of the tissue that was
cartilage and the total amount of cartilage at 6 weeks in a
dose-dependent manner compared with controls (P<0.05)
(Fig. 1). At a dose of 100 ng/ml of IGF-1, 87±5% of the
tissue formed was cartilage (vs 13±6% in the unstimulated
controls; P<0.05) and the explants formed greater total
amounts of cartilage (14±3 mg vs 0.6±0.3 mg; P<0.05).
There was no statistical difference between the total
amounts of cartilage formed with 100 versus 500 ng/ml, so
the concentration of 100 ng/ml was used as the ‘optimal’
IGF-1 dose for all subsequent studies involving IGF-1
treatment.EFFECT OF THE DURATION AND COMBINATION OF GROWTH
FACTORS ON PERIOSTEAL CHONDROGENESIS
Under the serum-free conditions used in this study, the
cartilage yield was not significantly increased by the
58 T. Fukumoto et al.: IGF-1 and TGF-1 in periosteal chondrogenesisFig. 1. Dose-dependent effects of IGF-1 on periosteal chondrogenesis. Periosteal explants were cultured with 0, 5, 10, 50, 100 or 500 ng/ml
IGF-1 for 6 weeks or for the first 2 days. After 6 weeks of culture, a cartilage yield assay was performed by measuring the % cartilage (A)
using computerized histomorphometry and the total amount of cartilage (B) which was calculated by multiplying % cartilage by wet weight.
Lower case letters (i.e. a, b and c) indicate the results of post-hoc testing with Duncan’s Multiple Range test at P<0.05. Groups with a letter
in common are not statistically different from one another. All data are presented ±S.E.Fig. 2. Effects of the durations and combinations of growth factors on periosteal chondrogenesis. Periosteal explants were cultured with one
of the following: (1) no growth factors, (2) 10 ng/mL TGF- for the first 2 days, (3) 100 ng/ml IGF-1 for the first 2 days, (4) IGF-1 for 6 weeks,
(5) TGF- and IGF-1 for the first 2 days, (6) IGF-1 for 6 weeks with TGF- for the first 2 days. After 6 weeks of culture, a cartilage yield
assay was performed by measuring the % cartilage (A) using computerized histomorphometry and the total amount of cartilage (B) which
was calculated by multiplying % cartilage by wet weight. Lower case letters (i.e. a, b and c) indicate the results of post-hoc testing with
Duncan’s Multiple Range test at P<0.05. Groups with a letter in common are not statistically different from one another. All data are
presented ±S.E.addition of IGF-1 alone for the first 2 days of culture
(16±7%) or by IGF-1 and TGF- combined for the first two
days of culture (34±9%) vs the yield in the control grouptreated with no growth factors (16±5%) [P>0.05, Fig. 2(A)).
However, the treatment of explants with 6 weeks of IGF-1
alone produced the highest cartilage yield (68±12%,
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of culture did not further enhance cartilage yield (64±15%).
As shown in Fig. 2(B), the total amount of cartilage
produced in the explants (i.e. % cartilage area×wet weight)
was also calculated. Significant increases in total cartilage
were only observed in the explants treated with IGF-1
(alone or with TGF-) for 6 weeks (P<0.05) when com-
pared to the control group (no growth factors). Although the
total amount of cartilage produced in the group treated with
IGF-1 for 6 weeks [Fig. 2(B)] was not as high as it was in
the dose response experiment, it was still significantly
higher than that seen in the control (no growth factors)
group (P<0.05). In this agarose culture system, the differ-
ences in the magnitude of the chondrogenic response
sometimes differ from experiment to experiment. However,
the trends of chondrogenic responses between treatment
groups within any one experiment are reproducible. As can
be seen in Fig. 2(b), the mean total cartilage produced in
the explants treated with IGF-1 alone for 6 weeks (4±2 mg)
was significantly higher than in the explants from the
control group (no growth factors) (1±0.2 mg), IGF-1 alone
for 2 days (0.4±0.2 mg) and IGF-1 for 2 days with TGF-
for 2 days (1±0.3 mg) groups (P<0.05). The mean total
cartilage produced in the explants treated with IGF-1 alone
for 2 days (0.4±0.3 mg) was not significantly different from
the total cartilage seen in the TGF- alone for 2 days group
(2±0.4 mg). The highest (P<0.05) total cartilage production
was observed in the explants treated with IGF-1 for
6 weeks plus TGF- for 2 days. The mean total cartilage in
this group (12±4 mg) was three times higher than in the
IGF-1 alone for 6 weeks group (4±2 mg), six times higher
than the TGF- alone for 2 days group (2±0.4 mg), and
over twelve times higher than the remaining 3 groups
[P<0.05, Fig. 2(B)].Table I
Cartilage yield time course
Time (w) No growth factors TGF-1 IGF-1 TGF-1+IGF-1
1 0a 0a 0a 6± 5a
2 6± 6a 12± 5a 21±12a 56± 8b
3 19±12a 30± 8ab 57±10ab 71±20b
4 30±15a 53±12ab 69±10bc 99± 0c
5 50± 5a 54±15a 83± 8b 97± 1b
6 56±21a 88± 6ab 87± 6ab 100± 0b
The cartilage yield represents the percent area of the explant that was cartilage as measured by Safranin O
staining and computerized histomorphometry. The superscript letters (a, b and c) represent grouping based
Duncan’s new multiple range post-hoc statistical testing at P<0.05 across treatment groups for each time point.
Cartilage yields within a given row with a letter in common, are not statistically different from one another (e.g. at
5 weeks: 50±5a≈54±15a and 83±8b≈97±1b).EFFECT OF THE COMBINATION OF GROWTH FACTORS ON
PROLIFERATION AND TYPE II COLLAGEN EXPRESSION
Based on these day 42 cartilage yield and total cartilage
results, a time course for the localization within the
cambium layer of proliferative activity (PCNA immunostain-
ing), type II collagen expression (in situ hybridization), and
overall Safranin O staining were done on explants treated
with either no growth factors, TGF-1 for the first 2 days of
culture, IGF-1 for all 6 weeks of culture or IGF-1 for all 6
weeks of culture with TGF-1 for the first 2 days of culture.
These treatment groups were evaluated at 1, 2, 3, 4, 5, and
6 weeks using four explants per group per time point.Examination of the histological sections stained with
Safranin O revealed a gradual increase in positive staining
matrix over time in all of the experimental groups. Auto-
mated histomorphometry and two-factor ANOVA of the
resulting data revealed that culture period and growth
factor treatment had a significant effect on cartilage yield
(P<0.0001). The mean cartilage yields for each treatment
group over time are summarized in Table I. At two weeks,
the earliest significant increase in cartilage yield was
induced by treatment with TGF-1+IGF-1 (P<0.05, Fig. 3).
At two weeks, the cartilage yield in the TGF-1+IGF-1
group was 56±8%. This was significantly higher (P<0.05)
than the cartilage yields seen with no growth factors
(6±6%), TGF-1 alone (12±5%) or IGF-1 alone (21±12%)
groups. By 28 days, the cartilage yield in the TGF-1+IGF-
1 group had reached a maximum while the cartilage yields
continued to increase in the other treatment groups up to
day 42. To examine the reasons behind this elevated and
accelerated cartilage yield in the TGF-1+IGF-1 group, we
looked to the proliferation (i.e. PCNA) and type II collagen
expression (i.e. in situ hybridization) data.
The proliferative index means for each treatment group
are summarized in Table II. Examination of the cambium
layer of the PCNA immunostained sections indicated an
increased level of proliferation in the explants treated
with IGF-1 in combination with TGF-1 [Fig. 4(A)]. Early
proliferative indices were maximal with IGF-1+TGF-1.
This treatment induced highest level of proliferation at 1
week [P<0.05, Fig. 4(B)]. At one week, the proliferative
index in the TGF-1+IGF-1 group was 49±6%. This was
significantly higher (P<0.05) than the proliferative indices
seen with no growth factors (15±3%), TGF-1 alone
(29±4%) or IGF-1 alone (31±6%) groups. Although statisti-
cal significance was not achieved at every time point,
elevated levels of PCNA staining were seen in both the
IGF-1 alone and the TGF-1+IGF-1 groups from two
weeks onward (Table II). In the explants treated with
TGF-1 alone, the proliferative index rose steadily for the
first 3 weeks. Then, from weeks 4 to 6, the proliferative
index of the TGF-1 group decreased to levels that were
not significantly different from those seen in the no growth
factor control group (P>0.05). This is in contrast to what
was observed in both of the IGF-1 treated groups that
exhibited proliferative indices that were significantly higher
than those seen in the no growth factor control and the
TGF-1 alone groups at 6 weeks (P<0.05).
The expression pattern of type II collagen mRNA is
summarized in Table III. In situ hybridization revealed that
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PCNA immunostaining proliferative index
Time (w) No growth factors TGF-1 IGF-1 TGF-1+IGF-1
1 15± 3a 29±4ab 31±6b 49±6c
2 15± 0a 61±4b 84±1c 81±1c
3 49±11a 76±1b 86±0b 83±2b
4 61± 3a 61±1a 81±1b 77±1b
5 61± 0a 65±2a 74±3ab 68±4b
6 40± 0a 44±0a 63±4b 67±4b
The proliferative index represents the percent of the cambium
cells that demonstrated positive immunostaining for PCNA (prolif-
erating nuclear cell antigen). The superscript letters (a, b and c)
represent grouping based Duncan’s new multiple range post-hoc
statistical testing at P<0.05 across treatment groups for each time
point. Proliferative indices within a given row with a letter in
common, are not statistically different from one another (e.g. at 4
weeks: 61±3a≈61±1a and 81±1b≈77±1b).Fig. 3. Cartilage formation at 2 weeks. Periosteal explants were cultured with no growth factors (No GFs), 10 ng/ml TGF-1 for the first 2
days (TGF-), 100 ng/ml IGF-1 for 6 weeks (IGF-1), or 10 ng/ml TGF-1 for the first 2 days with 100 ng/ml IGF-1 for 6 weeks (TGF-+IGF-1).
(A) Representative Safranin O/Fast Green histology of periosteal explants in each of the aforementioned groups at 2 weeks. (magnifica-
tion= ×200). (B) Cartilage yield analysis at 2 weeks via histomorphometry (n=4 explants per time point per group) demonstrating that that
the most cartilage was produced in the TGF-+IGF-1 group at this early time point (P<0.05). All data are presented ±S.E.Fig. 4. Immunohistochemistry for proliferative cell nuclear antigen (PCNA) at 1 week. Periosteal explants were cultured with no growth
factors (no GFs), 10 ng/ml TGF-1 for the first 2 days (TGF-), 100 ng/ml IGF-1 for 6 weeks (IGF-1), or 10 ng/ml TGF-1 for the first 2 days
with 100 ng/ml IGF-1 for 6 weeks (TGF-+IGF-1). (A) Representative photomicrographs of the PCNA immunostained periosteal explants in
each of the aforementioned groups at 1 week. (magnification= ×200). (B) Proliferation index analysis at one week via cell counting showing
that the highest level of proliferation at one week was induced when the explants were treated with TGF-+IGF-1 (P<0.05). All data are
presented±S.E. (four explants were assessed per time point per group).type II collagen expression was seen in all four treatment
groups at 3-6 weeks in the cambium layer (Fig. 5A). In the
growth-factor-treated explants, type II collagen expression
was seen starting at 2 weeks. In the explants treated with
IGF-1, the level of expression remained elevated through-
out the culture period (Fig. 5A). With TGF-1 alone, type II
collagen expression was seen in the juxtaosseous region of
the cambium layer (i.e. the region originally closest to the
bone35) at 2 weeks, then from 4–6 weeks, showed a similar
pattern as seen in the control group (no growth factors).
Detailed quantitative and statistical analysis revealed that,
at week 1 there was no significant difference in the type II
expression indices between the treatment groups. At
weeks 2 and 3, all of the growth-factor-treated groups had
type II expression indices that were significantly higher than
the unstimulated controls [Fig. 5(B)]. The type II collagen
expression index for the TGF-1 group decreased to the
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sion in the IGF-1-treated explants remained elevated
[P<0.05, Fig. 5(B)].Table III
In situ collagen II gene expression index
Time (w) No growth factors TGF-1 IGF-1 TGF-1+IGF-1
1 0± 0a 0±0a 0±0a 29±16a
2 0± 0a 78±3b 80±7b 76± 3b
3 40±19a 78±2b 81±2b 78± 3b
4 44± 4a 32±2a 73±6b 66± 5b
5 24± 2a 31±2a 74±3b 63± 7b
6 25± 1a 26±1a 73±5b 58± 3c
The in situ collagen II gene expression index represents the
percent of the cambium cells that demonstrated positive in situ
hybridization for Type II collagen mRNA. The superscript letters (a,
b and c) represent grouping based Duncan’s new multiple range
post-hoc statistical testing at P<0.05 across treatment groups for
each time point. Gene expression indices within a given row with a
letter in common, are not statistically different from one another
(e.g. at 4 weeks: 44±4a≈32±2a and 73±6b≈66±5b).Fig. 5. In situ hybridization for type II collagen at 3 and 6 weeks. Periosteal explants were cultured with no growth factors (no GFs), 10 ng/ml
TGF-1 for the first 2 days (TGF-), 100 ng/ml IGF-1 for 6 weeks (IGF-1), or 10 ng/ml TGF-1 for the first 2 days with 100 ng/ml IGF-1 for
6 weeks (TGF-+IGF-1). (A) Representative photomicrographs of the periosteal explants after in situ hybridization for type II collagen in
each of the aforementioned groups at 3 and 6 weeks. (magnification= ×200). (B) Type II Collagen expression index analysis at 3 and 6
weeks cell counting demonstrating that the Col2 expression was elevated in all of the growth factor treated explants (P<0.01) and was
maintained in the explants exposed to IGF-1 (P<0.01). The lowercase letters (a, b, or c) represent the results of means contrast testing. Bars
with letters in common are not statistically different from one another (P<0.03). All data are presented±S.E. (four explants were assessed per
time point per group).Discussion
Subperiosteal injection of TGF-1 has been known to
stimulate the proliferation of periosteal mesenchymal cells
and induce chondrogenic differentiation46,47. Previous
studies have reported that TGF-1 stimulates periosteum-
derived cells, as well as other mesenchymal cells48,49,toward chondrogenic differentiation50,51. We have pre-
viously observed that TGF-1 significantly increases
3H-thymidine incorporation into periosteal explants early
during chondrogenesis in vitro52. The effect of TGF-1 on
periosteal cell proliferation may depend on the conditions of
the target cells53,54.
We currently use 2 days of TGF- as our standard
culture model because we have observed that 14 days of
TGF-1 treatment is not significantly better than 2 days of
TGF-1 treatment36. Miura et al.55 showed that even very
brief exposures of high doses of TGF-1 (100 ng/mL for
30 min) had a dramatic effect on the amount of cartilage
produced in this culture system. Separate gene expression
studies by Davis et al. and Mizuta et al. suggest that a
2 day exposure to TGF-1 increases periosteal chondro-
genesis over 6 weeks because it directly or indirectly
up-regulates not only the expression of cartilage related
genes (aggrecan and collagen type II), but also the expres-
sion of endogenous TGF-1 and its receptors30,31.
We have previously observed induction of chondrogen-
esis in periosteal explants when cultured in agarose in the
presence of FBS without growth factors15,29. In this study,
explants were cultured in serum-free conditions to elimi-
nate any possible effects of serum. The cartilage yield (i.e.
% area cartilage) results with and without TGF-1 in this
study using 0.1% bovine serum albumin as a media sup-
plement are comparable to those reported previously
reported using 10% fetal bovine serum in this culture
model5,33,55,56. The Type II Collagen in situ data are also
comparable to those reported by Ito et al. using 10% fetal
bovine serum35.
62 T. Fukumoto et al.: IGF-1 and TGF-1 in periosteal chondrogenesisThe data from this study demonstrate that IGF-1 stimu-
lates periosteal chondrogenesis increasing both the rela-
tive and absolute amounts of cartilage in the periosteal
explants. However, unlike TGF-1, in order to cause such
an effect, IGF-1 had to be continuously present in the
media. IGF-1 has been reported to have effects on the
mitogenic activity and matrix synthesis of articular and
growth plate chondrocytes20,57–60. In addition, Bohme et al.
reported that IGF-1 stimulated proliferation and matrix
synthesis in embryonic sternal chondrocytes cultured in
agarose gel under serum-free conditions61. Also, with con-
tinuous IGF-1 treatment, the chondrocyte phenotype was
maintained and cells did not progress to the hypertrophic
stage61. However, the presence of FBS counteracted this
effect and elicited hypertrophy61.
While the effects of IGF-1 on undifferentiated mesen-
chymal cells in periosteum are not well known, our results
are consistent with prior reports. During bone development,
IGF-1 mRNA is expressed in the periosteum at the early
cartilage stage62. Izumi et al. reported that IGF-1 stimu-
lated DNA synthesis and type II collagen mRNA expression
in periosteum-derived cells63. Recently, Nixon et al.
observed that exogenous IGF-1 stimulation of bone
marrow-derived mesenchymal stem cells enhanced
chondrogenesis in full-thickness articular defect in vivo 64.
In separate in vitro studies, Gooch et al.65, and Madry et
al.66, demonstrated via exogenous administration65 and
gene transfection66, that long-term exposure to IGF-1 has a
beneficial effect on cartilage matrix production in bovine
chondrocytes.
In our study, long term IGF-1 supplementation resulted in
elevated and sustained PCNA staining. While the prolifer-
ative indices may be overestimates of active proliferation in
the periosteum because of the relatively long half-life of
PCNA67, it is clear that IGF-1 treatment increased PCNA
synthesis, and therefore, increased proliferation throughout
periosteal chondrogenesis. The addition of IGF-1 also
resulted in sustained type II collagen expression. The latter
observation supports the notion that IGF-1 plays a role in
the maintenance of cartilaginous phenotypic expression.
Several studies have reported the interactions of IGF-1
and TGF-1 on proliferation and differentiation of
chondrocytes59,68–70. In this study, IGF-1 in combination
with TGF-1 enhanced total cartilage production compared
with IGF-1 alone. It is interesting that there was an increase
in the total cartilage and no statistical difference in cartilage
yield with TGF-1 and IGF-1 compared to IGF-1 or TGF-1
alone. The earlier expression of type II collagen mRNA and
early induction of proliferation observed in the TGF-1 and
IGF-1 combined treatment group may explain the observed
differences in wet weights that resulted in the increased
total cartilage production in the combined treatment group
compared to IGF-1 alone.
Tsukazaki et al. showed that TGF- increased the
number of IGF-1 receptors in chondrocytes without chang-
ing their affinity69. O’Keefe et al. reported that IGF-1
enhanced the effect of TGF-1 on DNA synthesis in
chondrocytes58. Although it has not been ruled out that
TGF-1 can stimulate both the induction and the
progression/maintenance of chondrogenesis, these lines of
evidence suggest that IGF-1 and TGF-1 may interact to
stimulate the early induction of periosteal chondrogenesis,
which is then maintained with IGF-1 in the later stage.
The histomorphometry data in this study suggests that
the addition of IGF-1 and TGF-1 results in a dramatic
increase in overall growth in both the cartilaginous and
non-cartilaginous regions of the explants. It is likely thatcomplex interactions involving many growth factors at dif-
ferent stages of periosteal chondrogenesis are responsible
for its regulation. Further examination of their interactions
may reveal how periosteal chondrogenesis may be
enhanced not only for articular cartilage repair but also for
fracture healing.
The present study has demonstrated the combined
effects of TGF-1 and IGF-1 on chondrogenesis in perio-
steal explants. TGF-1 acted early to induce chondrogen-
esis, while IGF-1 enhanced and maintained proliferation,
increasing total cartilage formation. These observations
indicate that these factors could be useful to enhance
tissue-engineered articular cartilage repair.Acknowledgments
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